Pre-made Claudiximab benchmark antibody ( Whole mAb, anti-CLDN18 therapeutic antibody, Anti-SFTA5/SFTPJ Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Claudiximab biosimilar, Whole mAb, Anti-CLDN18 Antibody: Anti-SFTA5/SFTPJ therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Claudiximab is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-109-1mg	1mg	3090
GMP-Bios-ab-109-10mg	10mg	Inquiry
GMP-Bios-ab-109-100mg	100mg	Inquiry
GMP-Bios-ab-109-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Claudiximab biosimilar, Whole mAb, Anti-CLDN18 Antibody: Anti-SFTA5/SFTPJ therapeutic antibody
INN Name	Claudiximab
Target	CLDN18
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Ganymed Pharmaceuticals
Conditions Approved	na
Conditions Active	Gastric cancer;Oesophageal cancer;Pancreatic cancer
Conditions Discontinued	Solid tumours
Development Tech	na